Search by Drug Name or NDC
NDC 13811-0715-30 Venlafaxine Hydrochloride 225 mg/1 Details
Venlafaxine Hydrochloride 225 mg/1
Venlafaxine Hydrochloride is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Trigen Laboratories, LLC. The primary component is VENLAFAXINE HYDROCHLORIDE.
MedlinePlus Drug Summary
Venlafaxine is used to treat depression. Venlafaxine extended-release (long-acting) capsules are also used to treat generalized anxiety disorder (GAD; excessive worrying that is difficult to control), social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life), and panic disorder (sudden, unexpected attacks of extreme fear and worry about these attacks). Venlafaxine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance.
Related Packages: 13811-0715-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Venlafaxine
Product Information
| NDC | 13811-0715 |
|---|---|
| Product ID | 13811-715_523ad354-6ca2-4a14-b09d-797abaa359a4 |
| Associated GPIs | 58180090107540 |
| GCN Sequence Number | 064447 |
| GCN Sequence Number Description | venlafaxine HCl TAB ER 24 225 MG ORAL |
| HIC3 | H7C |
| HIC3 Description | SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS) |
| GCN | 14354 |
| HICL Sequence Number | 008847 |
| HICL Sequence Number Description | VENLAFAXINE HCL |
| Brand/Generic | Generic |
| Proprietary Name | Venlafaxine Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | venlafaxine hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 225 |
| Active Ingredient Units | mg/1 |
| Substance Name | VENLAFAXINE HYDROCHLORIDE |
| Labeler Name | Trigen Laboratories, LLC |
| Pharmaceutical Class | Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA AUTHORIZED GENERIC |
| Application Number | NDA022104 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 13811-0715-30 (13811071530)
| NDC Package Code | 13811-715-30 |
|---|---|
| Billing NDC | 13811071530 |
| Package | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (13811-715-30) |
| Marketing Start Date | 2010-04-29 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.75344 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | VENLAFAXINE HCL ER 225 MG TAB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1, 6 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |